Quick Answer
Matinas BioPharma Holdings, Inc. reported Total Revenue of $1.10 million for fiscal year 2023.
Matinas BioPharma Holdings, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | $1.10M -65.6% |
$3.19M +9560.6% |
$33.0K -79.2% |
$158.3K +76.3% |
| Revenue (ASC 606) | — | — | $1.10M -65.6% |
$3.19M +9560.6% |
$33.0K -79.2% |
$158.3K +76.3% |
| Net Income | -$10.35M +57.3% |
-$24.25M -5.7% |
-$22.94M -9.3% |
-$21.00M +9.8% |
-$23.28M -3.7% |
-$22.45M -29.2% |
| Diluted EPS | -$2.00 +59.8% |
-$4.98 +5.7% |
-$5.28 -5180.0% |
-$0.10 | — | — |
| Total Assets | $7.21M -43.0% |
$12.64M -49.6% |
$25.10M -44.0% |
$44.82M -26.9% |
$61.33M -13.6% |
$70.97M +76.4% |
| Cash and Equivalents | $4.00M -45.1% |
$7.28M +52.2% |
$4.79M -29.9% |
$6.83M -67.5% |
$21.03M +69.2% |
$12.43M -43.9% |
| Stockholders Equity | $4.83M -36.4% |
$7.59M -60.6% |
$19.25M -47.5% |
$36.64M -30.2% |
$52.49M -17.6% |
$63.73M +92.8% |
| R&D Expense | $85.0K -99.3% |
$11.43M -21.1% |
$14.49M -13.1% |
$16.68M +14.4% |
$14.58M +1.6% |
$14.36M +27.8% |
| Operating Income | -$6.96M +71.7% |
-$24.59M -3.5% |
-$23.77M +3.4% |
-$24.59M +0.6% |
-$24.73M -2.2% |
-$24.21M -27.9% |
| Shares Outstanding | 6.41M +25.9% |
5.09M +17.1% |
4.35M -98.0% |
217.26M +0.5% |
216.27M +8.1% |
200.11M +21053.6% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | March 31, 2023 | $1.10M | — | +3.1% |
| Revenue (ASC 606) | March 31, 2023 | $1.10M | — | +3.1% |
| Net Income | September 30, 2025 | -$1.53M | +64.2% | +70.8% |
| Diluted EPS | September 30, 2025 | -$0.40 | +52.9% | +61.2% |
| Total Assets | September 30, 2025 | $9.70M | -52.9% | -15.1% |
| Cash and Equivalents | September 30, 2025 | $5.43M | -47.2% | -16.7% |
| Stockholders Equity | September 30, 2025 | $6.46M | -59.1% | -15.8% |
| R&D Expense | March 31, 2025 | $85.0K | -97.5% | -96.2% |
| Operating Income | September 30, 2025 | -$1.58M | +64.0% | +14.2% |
| Shares Outstanding | September 30, 2025 | 5.90M | +16.0% | +16.0% |
- Matinas BioPharma Holdings, Inc. reported Total Revenue of $1.10 million for fiscal year 2023.
- Matinas BioPharma Holdings, Inc. showed a decrease of -65.6% in Total Revenue compared to the prior fiscal year.
- Matinas BioPharma Holdings, Inc. reported Revenue (ASC 606) of $1.10 million for fiscal year 2023.
- Matinas BioPharma Holdings, Inc. showed a decrease of -65.6% in Revenue (ASC 606) compared to the prior fiscal year.
- Matinas BioPharma Holdings, Inc. reported Net Income of -$10.35 million for fiscal year 2025.
- Matinas BioPharma Holdings, Inc. showed an increase of +57.3% in Net Income compared to the prior fiscal year.
- Matinas BioPharma Holdings, Inc. reported Diluted EPS of $2.00 per share (loss) for fiscal year 2025.
- Matinas BioPharma Holdings, Inc. showed an increase of +59.8% in Diluted EPS compared to the prior fiscal year.
- Matinas BioPharma Holdings, Inc. reported Total Assets of $7.21 million for fiscal year 2025.
- Matinas BioPharma Holdings, Inc. showed a decrease of -43.0% in Total Assets compared to the prior fiscal year.
- Matinas BioPharma Holdings, Inc. reported Cash and Equivalents of $4.00 million for fiscal year 2025.
- Matinas BioPharma Holdings, Inc. showed a decrease of -45.1% in Cash and Equivalents compared to the prior fiscal year.
- Matinas BioPharma Holdings, Inc. reported Stockholders Equity of $4.83 million for fiscal year 2025.
- Matinas BioPharma Holdings, Inc. showed a decrease of -36.4% in Stockholders Equity compared to the prior fiscal year.
- Matinas BioPharma Holdings, Inc. reported R&D Expense of $85.0 thousand for fiscal year 2025.
- Matinas BioPharma Holdings, Inc. showed a decrease of -99.3% in R&D Expense compared to the prior fiscal year.
- Matinas BioPharma Holdings, Inc. reported Operating Income of -$6.96 million for fiscal year 2025.
- Matinas BioPharma Holdings, Inc. showed an increase of +71.7% in Operating Income compared to the prior fiscal year.
- Matinas BioPharma Holdings, Inc. reported Shares Outstanding of 6.41 million shares for fiscal year 2025.
- Matinas BioPharma Holdings, Inc. showed an increase of +25.9% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: